Option chain shows key data for Soligenix's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Soligenix.

Soligenix (NASDAQ:SNGX) Stock, Option Chain

Soligenix

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).

Screenshot 2025-05-02 at 5.43.08 PM

Biotech

SNGX

Soligenix Issues Interim Results For CTCL Treatment Trial – 75% Response At 18 Weeks, 3 Patients Achieve Complete Response

Screenshot 2025-04-23 at 10.53.10 PM

General

Soligenix&#39;s HyBryte™ Shows 75% Response Rate In Skin Cancer Trial, Backed By FDA Funding

Screenshot 2025-02-24 at 11.30.54 PM

Interview

Soligenix Aims To Push The Boundaries In Treating Rare Diseases

Soligenix Inc

Press Releases

HyBryte™ Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma

Soligenix to Present at Upcoming Investor Conferences

Soligenix Targets Psoriasis With New Therapy

Small Cap

Soligenix to Present at BIO CEO & Investor Conference

HyBryte™ Treatment Studies Presented at Two Medical Conferences in March

Earnings

Soligenix Announces Recent Accomplishments and Year End 2024 Financial Results

Soligenix Announces Publication Demonstrating CiVax™ Booster Induces Rapid Broad Protection Against COVID-19 Variants

IBN Initiates Coverage of Soligenix Inc.

Positive Outcome in 75% of CTCL Patients Treated with HyBryte™ for 18 Weeks

AEON Biopharma, Inc. Class A Common Stock

AEON Biopharma

Alzamend Neuro

Apollomics Inc. - Class A Ordinary Shares

Apollomics

Aptorum Group Limited - Class A Ordinary Shares

Aptorum Gr

180 Life Sciences

Azitra

Brainstorm Cell Therapeutics Inc. - Common Stock

Brainstorm Cell

Creative Medical Technology Holdings, Inc. - Common Stock

Creative Medical Tech

CERo Therapeutics Holdings, Inc. - Common Stock

CERo Therapeutics Hldgs

Channel Therapeutics Corporation Common Stock

Channel Therapeutics

Dermata Therapeutics, Inc. - Common Stock

Dermata Therapeutics

Ensysce Biosciences

GT Biopharma

Indaptus Therapeutics, Inc. - Common Stock

Indaptus Therapeutics

Klotho Neurosciences, Inc. - Common Stock

Klotho Neurosciences

Lipella Pharmaceuticals Inc. - Common Stock

Lipella Pharmaceuticals

MetaVia

Mainz Biomed

PharmaCyte Biotech

Palatin Techs

Sunshine Biopharma

Sonnet BioTherapeutics Holdings, Inc. - Common Stock

Sonnet BioTherapeutics

Turnstone Biologics

Longevity Health Holdings, Inc. - Common Stock

Longevity Health Holdings

XTL Biopharmaceuticals Ltd. - American Depositary Shares

Comments

Soligenix

Soligenix (SNGX) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell